Structures by: Aitipamula S.
Total: 140
Zonisamide-2-hydroxy-5-methylpyridine
C8H8N2O3S,C6H7NO
CrystEngComm (2018) 20, 21 2923
a=14.1373(3)Å b=11.23707(18)Å c=9.45521(17)Å
α=90.00° β=106.2761(19)° γ=90.00°
Zonisamide:Caffeine
C8H8N2O3S,C8H10N4O2
CrystEngComm (2018) 20, 21 2923
a=9.59020(10)Å b=13.30840(10)Å c=14.24360(10)Å
α=90° β=91.8550(10)° γ=90°
Form II of 1:1 cocrystal of ethenzamide and gentisic acid
C9H11NO2,C7H6O4
CrystEngComm (2009) 11, 9 1823
a=7.7217(15)Å b=12.668(3)Å c=15.749(3)Å
α=90.00° β=102.44(3)° γ=90.00°
Form III of 1:1 cocrystal of ethenzamide and gentisic acid
C9H11NO2,C7H6O4
CrystEngComm (2009) 11, 9 1823
a=7.1283(14)Å b=16.242(3)Å c=12.904(3)Å
α=90.00° β=96.25(3)° γ=90.00°
Form I of 1:1 cocrystal of ethenzamide and gentisic acid
C9H11NO2,C7H6O4
CrystEngComm (2009) 11, 9 1823
a=8.0485(16)Å b=9.1139(18)Å c=22.607(5)Å
α=94.13(3)° β=91.52(3)° γ=113.94(3)°
Form I of 1:1 cocrystal of ethenzamide and saccharin
C9H11NO2,C7H5NO3S
CrystEngComm (2009) 11, 5 889
a=7.2141(14)Å b=7.4923(15)Å c=15.456(3)Å
α=85.14(3)° β=86.43(3)° γ=70.65(3)°
Form II of 1:1 cocrystal of ethenzamide and saccharin
C9H11NO2,C7H5NO3S
CrystEngComm (2009) 11, 5 889
a=8.6125(17)Å b=16.607(3)Å c=11.183(2)Å
α=90.00° β=91.45(3)° γ=90.00°
Bis(4-nitrophenyl)diphenylmethane
C25H18N2O4
CrystEngComm (2004) 6, 25 120
a=7.5520(15)Å b=16.296(3)Å c=16.174(3)Å
α=90.00° β=98.71(3)° γ=90.00°
Tetrakis-(4-cyanophenyl)methane
C29H16N4
CrystEngComm (2004) 6, 25 120
a=9.782(1)Å b=11.907(2)Å c=20.242(3)Å
α=90.00° β=98.13(1)° γ=90.00°
Tetrakis-(4-cyanophenyl)methane-MeCN
C29H16N4
CrystEngComm (2004) 6, 25 120
a=15.413(3)Å b=17.607(3)Å c=18.504(3)Å
α=90.00° β=90.00° γ=90.00°
Bis(4-nitrophenyl)diphenylmethane-water
C75H58N6O14
CrystEngComm (2004) 6, 25 120
a=20.909(2)Å b=20.909(2)Å c=25.247(4)Å
α=90.00° β=90.00° γ=120.00°
Bis(4-nitrophenyl)diphenylmethane-THF
C78H54N6O16
CrystEngComm (2004) 6, 25 120
a=20.916(3)Å b=20.916(3)Å c=25.122(5)Å
α=90.00° β=90.00° γ=120.00°
2-chloro-4-nitrobenzoic acid hydrate
C7H4ClNO4,H2O
CrystEngComm (2011) 13, 3 1037
a=7.2871(15)Å b=7.9395(16)Å c=8.5516(17)Å
α=117.58(3)° β=95.80(3)° γ=93.48(3)°
1,4-dioxane solvate of 2-chloro-4-nitrobenzoic acid
C7H4ClNO4,0.5(C4H8O2)
CrystEngComm (2011) 13, 3 1037
a=6.918(3)Å b=8.368(3)Å c=9.714(3)Å
α=106.777(2)° β=93.774(4)° γ=108.433(5)°
Acetophenone solvate of 2-chloro-4-nitrobenzoic acid
C7H4ClNO4,C8H8O
CrystEngComm (2011) 13, 3 1037
a=5.8156(12)Å b=10.387(2)Å c=12.207(2)Å
α=83.67(3)° β=77.63(3)° γ=81.03(3)°
P-xylene solvate of 2-chloro-4-nitrobenzoic acid
C8H10,2(C7H4ClNO4)
CrystEngComm (2011) 13, 3 1037
a=10.790(2)Å b=11.767(2)Å c=8.9666(18)Å
α=90.00° β=90.71(3)° γ=90.00°
Mesitylene solvate of 2-chloro-4-nitrobenzoic acid
C9H12,2(C7H4ClNO4)
CrystEngComm (2011) 13, 3 1037
a=23.088(5)Å b=12.018(2)Å c=8.9206(18)Å
α=90.00° β=110.29(3)° γ=90.00°
Sulfamerazine-1,4-dioxane (1:1)
C15H20N4O4S
CrystEngComm (2012) 14, 2 691
a=11.511(2)Å b=12.436(3)Å c=12.095(2)Å
α=90.00° β=102.05(3)° γ=90.00°
Sulfamerazine-1,4-dioxane (1:0.5)
C13H16N4O3S
CrystEngComm (2012) 14, 2 691
a=7.7675(16)Å b=8.1233(16)Å c=12.631(3)Å
α=91.16(3)° β=95.69(3)° γ=105.23(3)°
Sulfamerazine-dimethylformamide(1:1)
C11H12N4O2S,C3H7NO
CrystEngComm (2012) 14, 2 691
a=9.774(2)Å b=12.556(3)Å c=14.659(3)Å
α=76.58(3)° β=77.57(3)° γ=86.18(3)°
Sulfamerazine-dimethylacetamide(1:1)
C15H21N5O3S
CrystEngComm (2012) 14, 2 691
a=7.6792(15)Å b=8.3101(17)Å c=15.125(3)Å
α=93.13(3)° β=101.81(3)° γ=104.77(3)°
Sulfamerazine-cyclopentanone(1:1)
C16H20N4O3S
CrystEngComm (2012) 14, 2 691
a=5.9650(12)Å b=9.6479(19)Å c=14.817(3)Å
α=76.16(3)° β=83.05(3)° γ=89.71(3)°
Sulfamerazine-3-Picoline(1:1)
C17H19N5O2S
CrystEngComm (2012) 14, 2 691
a=7.8319(16)Å b=8.1117(16)Å c=15.358(3)Å
α=76.47(3)° β=77.04(3)° γ=73.54(3)°
Monohydrate of Piracetam-4-hydroxybenzoic acid (1:1)
C13H18N2O6
CrystEngComm (2012) 14, 7 2381
a=6.4211(13)Å b=6.6058(13)Å c=16.590(3)Å
α=96.20(3)° β=96.76(3)° γ=90.86(3)°
MOnohydrate of caffeine-4HBA (1:1)
C15H18N4O6
CrystEngComm (2012) 14, 7 2381
a=7.2188(14)Å b=8.5282(17)Å c=13.827(3)Å
α=90.33(3)° β=101.29(3)° γ=107.57(3)°
Oxaprozin-1,2-bis(4-pyridyl)ethane
C18H15NO3,C6H6N
RSC Adv. (2016)
a=9.7069(19)Å b=10.878(2)Å c=10.907(2)Å
α=76.50(3)° β=68.03(3)° γ=66.04(3)°
Oxaprozin-Salbutamol
C13H22NO3,C18H14NO3
RSC Adv. (2016)
a=10.453(2)Å b=10.627(2)Å c=13.379(3)Å
α=76.02(3)° β=69.82(3)° γ=88.05(3)°
Oxaprozin-4,4'-Bipyridine
C18H15NO3,C5H4N
RSC Adv. (2016)
a=13.422(3)Å b=15.305(3)Å c=18.618(4)Å
α=90.00° β=103.53(3)° γ=90.00°
Oxaprozin
C18H15NO3
RSC Adv. (2016)
a=10.3129(5)Å b=7.6460(3)Å c=36.7642(15)Å
α=90.00° β=90.00° γ=90.00°
Oxaprozin-piperazine
C18H14NO3,C2H6N
RSC Adv. (2016)
a=5.8155(12)Å b=7.3355(15)Å c=19.744(4)Å
α=90.14(3)° β=91.13(3)° γ=99.08(3)°
DMSO solvate of 2-chloro-4-nitrobenzoic acid
C7H4ClNO4,C2H6OS
CrystEngComm (2011) 13, 3 1037
a=5.497(3)Å b=10.408(4)Å c=10.594(4)Å
α=74.095(15)° β=81.029(12)° γ=85.487(16)°
Oxaprozin-2-Amino-3-Picoline
C18H14NO3,C6H9N2
RSC Adv. (2016)
a=6.0156(12)Å b=8.8644(18)Å c=19.296(4)Å
α=81.31(3)° β=85.29(3)° γ=80.23(3)°
C15H10Cl2N2O2,C6H6N2O
C15H10Cl2N2O2,C6H6N2O
CrystEngComm (2017)
a=20.6918(6)Å b=4.61421(12)Å c=20.1099(5)Å
α=90.0° β=90.673(2)° γ=90.0°
C15H9.5Cl2N2O2,C15H9Cl2N2O2,C3H5N2,C3H4.5N2
C15H9.5Cl2N2O2,C15H9Cl2N2O2,C3H5N2,C3H4.5N2
CrystEngComm (2017)
a=10.0605(5)Å b=11.0252(6)Å c=16.3298(10)Å
α=88.224(4)° β=76.212(5)° γ=84.969(4)°
2(C15H9Cl2N2O2),2(C2H6N)
2(C15H9Cl2N2O2),2(C2H6N)
CrystEngComm (2017)
a=11.6186(5)Å b=12.3390(8)Å c=12.5559(7)Å
α=68.926(6)° β=85.447(4)° γ=88.975(4)°
C15H9Cl2N2O2,C5H7N2
C15H9Cl2N2O2,C5H7N2
CrystEngComm (2017)
a=11.1266(5)Å b=22.3945(10)Å c=8.5821(5)Å
α=90° β=106.718(6)° γ=90°
L3-79-B
C15H10Cl2N2O2,2(C4H5N3)
CrystEngComm (2017)
a=14.1417(6)Å b=21.6532(8)Å c=7.6525(3)Å
α=90° β=102.654(4)° γ=90°
2(C15H9.5Cl2N2O2),C3H5N2
2(C15H9.5Cl2N2O2),C3H5N2
CrystEngComm (2017)
a=10.3787(7)Å b=11.8719(9)Å c=14.0409(8)Å
α=105.139(6)° β=91.651(5)° γ=91.906(6)°
C15H10Cl2N2O2
C15H10Cl2N2O2
CrystEngComm (2017)
a=19.3743(10)Å b=4.7313(2)Å c=14.6770(7)Å
α=90° β=91.886(4)° γ=90°
C15H9Cl2N2O2,C3H5N2,0.5(C4H8O2)
C15H9Cl2N2O2,C3H5N2,0.5(C4H8O2)
CrystEngComm (2017)
a=15.1394(5)Å b=29.9418(9)Å c=26.9456(6)Å
α=90° β=97.628(2)° γ=90°
C15H9Cl2N2O2,C5H7N2,C4H8O2
C15H9Cl2N2O2,C5H7N2,C4H8O2
CrystEngComm (2017)
a=10.9724(3)Å b=13.1874(3)Å c=8.8415(3)Å
α=90° β=109.768(3)° γ=90°
2(C15H10Cl2N2O2),C10H8N2
2(C15H10Cl2N2O2),C10H8N2
CrystEngComm (2017)
a=32.6725(11)Å b=26.2388(13)Å c=8.6827(3)Å
α=90° β=93.879(3)° γ=90°
C15H10Cl2N2O2,C7H7NO
C15H10Cl2N2O2,C7H7NO
CrystEngComm (2017)
a=18.3534(8)Å b=10.1000(3)Å c=11.0376(4)Å
α=90° β=99.146(4)° γ=90°
C15H10Cl2N2O2,C6H6N2O
C15H10Cl2N2O2,C6H6N2O
CrystEngComm (2017)
a=12.9910(3)Å b=7.6724(2)Å c=19.8344(5)Å
α=90° β=97.409(2)° γ=90°
C15H9Cl2N2O2,C3H7N6
C15H9Cl2N2O2,C3H7N6
CrystEngComm (2017)
a=7.0752(4)Å b=8.1750(4)Å c=16.8057(10)Å
α=99.416(5)° β=100.168(5)° γ=94.778(5)°
C15H10Cl2N2O2,C15H9Cl2N2O2,C7H11N2
C15H10Cl2N2O2,C15H9Cl2N2O2,C7H11N2
CrystEngComm (2017)
a=8.5711(2)Å b=12.3681(4)Å c=16.6270(5)Å
α=79.963(3)° β=81.329(2)° γ=84.947(3)°
C15H9Cl2N2O2,C7H11N2,2(H2O)
C15H9Cl2N2O2,C7H11N2,2(H2O)
CrystEngComm (2017)
a=13.0507(2)Å b=9.0330(2)Å c=19.0712(4)Å
α=90° β=99.214(2)° γ=90°
C15H9Cl2N2O2,C4H8N5
C15H9Cl2N2O2,C4H8N5
CrystEngComm (2017)
a=7.77896(16)Å b=31.5718(7)Å c=7.72521(16)Å
α=90° β=97.1388(19)° γ=90°
Triflusal-BA cocrystal
C10H7F3O4,C7H7NO
CrystEngComm (2015) 17, 48 9323
a=5.1765(10)Å b=15.228(3)Å c=21.041(4)Å
α=90° β=93.91(3)° γ=90°
Triflusal-Isonicotinamide cocrystal
C10H7F3O4,C6H6N2O
CrystEngComm (2015) 17, 48 9323
a=17.345(7)Å b=5.1415(17)Å c=19.447(7)Å
α=90° β=112.506(5)° γ=90°
Triflusal-2-Picoliniamide cocrystal
C10H7F3O4,C6H6N2O
CrystEngComm (2015) 17, 48 9323
a=5.5536(11)Å b=11.950(2)Å c=12.200(2)Å
α=96.01(3)° β=94.85(3)° γ=95.99(3)°
Triflusal-urea cocrystal
CH4N2O,2(C10H7F3O4)
CrystEngComm (2015) 17, 48 9323
a=14.601(3)Å b=10.920(2)Å c=15.342(3)Å
α=90° β=102.49(3)° γ=90°
Triflusal-Propionamide cocrystal
C10H7F3O4,C3H7NO
CrystEngComm (2015) 17, 48 9323
a=18.729(6)Å b=9.921(3)Å c=8.067(3)Å
α=90° β=97.605(4)° γ=90°
Triflusal-valpromide cocrystal
C10H7F3O4,C8H17NO
CrystEngComm (2015) 17, 48 9323
a=19.8545(8)Å b=5.06409(17)Å c=21.8530(11)Å
α=90° β=114.362(6)° γ=90°
C33H25BF15NSi2Zr
C33H25BF15NSi2Zr
Dalton transactions (Cambridge, England : 2003) (2010) 39, 3 807-814
a=11.245(2)Å b=13.098(3)Å c=13.383(3)Å
α=77.57(3)° β=67.01(3)° γ=74.56(3)°
C20H20F5NSi2Zr
C20H20F5NSi2Zr
Dalton transactions (Cambridge, England : 2003) (2010) 39, 3 807-814
a=11.491(2)Å b=10.952(2)Å c=17.244(3)Å
α=90.00° β=100.20(3)° γ=90.00°
C53H43BF20N2Si4Zr2
C53H43BF20N2Si4Zr2
Dalton transactions (Cambridge, England : 2003) (2010) 39, 3 807-814
a=12.554(3)Å b=15.672(3)Å c=16.284(3)Å
α=100.12(3)° β=103.26(3)° γ=111.69(3)°
1:1 ethenzamide and salicylic acid cocrystal
C9H11NO2,C7H6O3
CrystEngComm (2012) 14, 24 8515
a=10.679(2)Å b=9.6670(19)Å c=14.845(3)Å
α=90.00° β=106.97(3)° γ=90.00°
1:1 ethenzamide and vanillic acid cocrystal
C9H11NO2,C8H8O4
CrystEngComm (2012) 14, 24 8515
a=13.774(3)Å b=14.911(3)Å c=8.0828(16)Å
α=90.00° β=102.87(3)° γ=90.00°
1:1 cocrystal of ethenzamide and 2-chloro-4-nitrobenzoic acid
C9H11NO2,C7H4ClNO4
CrystEngComm (2012) 14, 24 8515
a=7.7402(15)Å b=8.3181(17)Å c=13.216(3)Å
α=76.02(3)° β=79.85(3)° γ=84.69(3)°
2:1 ethenzamide and 4-aminobenzoic acid cocrystal
2(C9H11NO2),C7H7NO2
CrystEngComm (2012) 14, 24 8515
a=9.0570(18)Å b=32.685(7)Å c=8.1857(16)Å
α=90.00° β=93.39(3)° γ=90.00°
1:1 ethenzamide and 4-hydroxybenzoic acid
C9H11NO2,C7H6O3
CrystEngComm (2012) 14, 24 8515
a=9.4871(19)Å b=6.4682(13)Å c=23.703(5)Å
α=90.00° β=98.65(3)° γ=90.00°
1:0.5 ethenzamide and fumaric acid cocrystal
C9H11NO2,0.5(C4H4O4)
CrystEngComm (2012) 14, 24 8515
a=8.2154(16)Å b=8.4654(17)Å c=9.3991(19)Å
α=70.30(3)° β=71.82(3)° γ=65.97(3)°
4,4-bis(4-hydroxyphenyl)cyclohexanone
C18H18O3
CrystEngComm (2003) 5, 78 447
a=14.391(3)Å b=20.228(4)Å c=9.782(2)Å
α=90.00° β=91.96(3)° γ=90.00°
4,4-bis(3-methyl-4-hydroxyphenyl)cyclohexanone
C20H22O3
CrystEngComm (2003) 5, 78 447
a=10.004(2)Å b=15.783(3)Å c=20.253(4)Å
α=90.00° β=94.79(3)° γ=90.00°
C21H18F3N5O4
C21H18F3N5O4
CrystEngComm (2014) 16, 26 5793
a=6.9931(14)Å b=10.127(2)Å c=15.112(3)Å
α=95.46(3)° β=96.70(3)° γ=101.17(3)°
C19H15F3N2O3
C19H15F3N2O3
CrystEngComm (2014) 16, 26 5793
a=7.5628(15)Å b=7.6450(15)Å c=14.552(3)Å
α=90.45(3)° β=92.14(3)° γ=95.81(3)°
C38H28F6N4O4
C38H28F6N4O4
CrystEngComm (2014) 16, 26 5793
a=9.827(2)Å b=10.361(2)Å c=25.005(5)Å
α=84.67(3)° β=81.34(3)° γ=71.46(3)°
C13H15N3O5
C13H15N3O5
CrystEngComm (2013) 15, 29 5877
a=7.0070(14)Å b=11.224(2)Å c=16.950(3)Å
α=90.00° β=91.95(3)° γ=90.00°
C13H15N3O5
C13H15N3O5
CrystEngComm (2013) 15, 29 5877
a=6.8143(14)Å b=22.419(5)Å c=8.8759(18)Å
α=90.00° β=101.85(3)° γ=90.00°
C16H18N6O6
C16H18N6O6
CrystEngComm (2013) 15, 29 5877
a=7.8906(16)Å b=8.7030(17)Å c=12.517(3)Å
α=90.00° β=97.84(3)° γ=90.00°
C16H18N6O6
C16H18N6O6
CrystEngComm (2013) 15, 29 5877
a=3.7036(7)Å b=7.8401(16)Å c=29.573(6)Å
α=90.00° β=90.63(3)° γ=90.00°
C16H17N5O6
C16H17N5O6
CrystEngComm (2013) 15, 29 5877
a=5.0595(10)Å b=17.246(3)Å c=19.056(4)Å
α=90.00° β=97.25(3)° γ=90.00°
C16H19N5O6
C16H19N5O6
CrystEngComm (2013) 15, 29 5877
a=5.1175(10)Å b=17.467(4)Å c=18.763(4)Å
α=90.00° β=96.71(3)° γ=90.00°
Form I cocrystal of ethenzamide with ethylmalonic acid
C9H11NO2,C5H8O4
CrystEngComm (2010) 12, 11 3691
a=7.6928(15)Å b=8.8062(18)Å c=11.575(2)Å
α=93.04(3)° β=108.70(3)° γ=91.72(3)°
Form II of ethenzamide and ethylmalonic acid cocrystal
C9H11NO2,C5H8O4
CrystEngComm (2010) 12, 11 3691
a=14.501(3)Å b=7.6438(15)Å c=14.323(3)Å
α=90.00° β=108.45(3)° γ=90.00°
Form II cocrystal of 1:1 ethenzamide and ethylmalonic acid cocrystal
C9H11NO2,C5H8O4
CrystEngComm (2010) 12, 11 3691
a=14.463(3)Å b=7.6366(15)Å c=14.296(3)Å
α=90.00° β=108.42(3)° γ=90.00°
Form 1 of 1:1 nicotinamide and pimelic acid
C7H12O4,C6H6N2O
CrystEngComm (2012) 14, 23 8193
a=5.4242(11)Å b=7.3161(15)Å c=17.917(4)Å
α=99.69(3)° β=94.01(3)° γ=103.93(3)°
Form 2 of 1:1 nicotinamide and pimelic acid
C7H12O4,C6H6N2O
CrystEngComm (2012) 14, 23 8193
a=9.290(7)Å b=31.04(2)Å c=4.981(4)Å
α=90.00° β=90.00° γ=90.00°
C15H17NO2,C6H6O2
C15H17NO2,C6H6O2
Acta Crystallographica Section B (2019) 75, 6
a=7.20150(10)Å b=12.23260(10)Å c=21.3487(3)Å
α=90° β=90° γ=90°
Polymorph of Agometaline-hydroquinone (1:1) cocrystal
C15H17NO2,C6H6O2,
Acta Crystallographica Section B (2019) 75, 6
a=7.33300(10)Å b=29.3095(4)Å c=8.80460(10)Å
α=90° β=94.7480(10)° γ=90°
C19H20ClNO6
C19H20ClNO6
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 1 54-62
a=11.783(2)Å b=8.5387(17)Å c=19.297(4)Å
α=90.00° β=96.03(3)° γ=90.00°
C18H20ClNO8
C18H20ClNO8
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 1 54-62
a=8.5456(17)Å b=11.740(2)Å c=19.269(4)Å
α=90.00° β=90.00° γ=90.00°
C36H39Cl2NO14
C36H39Cl2NO14
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 1 54-62
a=8.6852(17)Å b=15.047(3)Å c=27.605(6)Å
α=90.00° β=90.00° γ=90.00°
C19H22ClNO8
C19H22ClNO8
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 1 54-62
a=21.931(4)Å b=8.6541(17)Å c=11.797(2)Å
α=90.00° β=117.57(3)° γ=90.00°
1,1,1-tris(4-hydroxyphenyl)methane--bipyridine (1/1)
C19H16O3,C10H8N2
Acta Crystallographica Section C (2003) 59, 8 o481-o484
a=26.483(5)Å b=34.102(7)Å c=10.483(2)Å
α=90.00° β=90.00° γ=90.00°
Tris(4-hydroxyphenyl)methane
C19H16O3
Acta Crystallographica Section C (2003) 59, 8 o481-o484
a=12.326(3)Å b=18.573(4)Å c=7.4961(15)Å
α=90.00° β=114.36(3)° γ=90.00°
Ethenzamide--gentisic acid--acetic acid (2/1/1)
2(C9H11NO2),C7H6O4,C2H4O2
Acta Crystallographica Section E (2010) 66, 5 o1045-o1046
a=8.8083(18)Å b=8.8802(18)Å c=19.880(4)Å
α=93.65(3)° β=93.55(3)° γ=119.45(3)°
Pyrimidin-2-amine--1-phenylcyclopentane-1-carboxylic acid (1/1)
C4H5N3,C12H14O2
Acta Crystallographica Section E (2011) 67, 3 o552-o553
a=9.1461(18)Å b=10.490(2)Å c=15.474(3)Å
α=90.00° β=98.14(3)° γ=90.00°
1:1 cocrystal of theophylline and gentisic acid
C7H8N4O2,C7H6O4
Acta Crystallographica Section E (2009) 65, 9 o2126-o2127
a=7.0989(14)Å b=8.0543(16)Å c=13.034(3)Å
α=86.08(3)° β=81.27(3)° γ=74.14(3)°
2-Aminopyridinium 1-phenylcyclopropane-1-carboxylate
C5H7N2,C10H9O2
Acta Crystallographica Section E (2010) 66, 12 o3339-o3340
a=8.6147(17)Å b=9.0555(18)Å c=9.2346(18)Å
α=75.56(3)° β=87.72(3)° γ=72.79(3)°
<i>N</i>,<i>N</i>-Dimethylpyridin-4-aminium 1-phenylcyclopentane-1-carboxylate monohydrate
C7H11N2,C12H13O2,H2O
Acta Crystallographica Section E (2011) 67, 5 o1227
a=6.1666(12)Å b=18.206(4)Å c=15.702(3)Å
α=90.00° β=97.33(3)° γ=90.00°
Haloperidol-oxalic acid dihydrate
C44H52Cl2F2N2O10
Crystal Growth & Design (2014) 14, 5 2542
a=11.961(2)Å b=12.954(3)Å c=14.825(3)Å
α=114.00(3)° β=99.25(3)° γ=90.72(3)°
ACN solvate of HAL and OA salt
C46H51Cl2F2N3O8
Crystal Growth & Design (2014) 14, 5 2542
a=13.125(3)Å b=11.996(2)Å c=26.810(5)Å
α=90.00° β=90.06(3)° γ=90.00°
Haloperidol-fumaric acid salt dihydrate
C23H29ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.7151(17)Å b=10.152(2)Å c=14.454(3)Å
α=97.42(3)° β=98.87(3)° γ=114.92(3)°
Haloperidol-succinic acid salt hydrate
C23H30ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.6026(17)Å b=10.585(2)Å c=13.862(3)Å
α=108.39(3)° β=101.96(3)° γ=99.31(3)°
Haloperidol-Acetic acid salt dihydrate
C23H31ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.7476(17)Å b=10.374(2)Å c=13.837(3)Å
α=105.57(3)° β=100.04(3)° γ=96.10(3)°
Haloperidol-Formic acid salt
C23H27ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.4958(17)Å b=10.032(2)Å c=26.324(5)Å
α=90.00° β=94.46(3)° γ=90.00°
1:1 salt of haloperidol and saccharin
C28H28ClFN2O5S
Crystal Growth & Design (2014) 14, 5 2542
a=11.189(2)Å b=19.890(4)Å c=12.562(3)Å
α=90.00° β=114.22(3)° γ=90.00°
1:1 salt of HAL and CSA
C27H36ClFN2O5S
Crystal Growth & Design (2014) 14, 5 2542
a=8.4571(17)Å b=9.768(2)Å c=17.989(4)Å
α=87.28(3)° β=86.32(3)° γ=68.48(3)°